Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04300244
Title Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)
Acronym NIPU
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Aslaug Helland
Age Groups: adult | senior
Covered Countries ESP | AUS

No variant requirements are available.